| POPRACH, A., Tomáš PAVLÍK, B. MELICHAR, K. KUBACKOVA, Zbyněk BORTLÍČEK, M. SVOBODA, R. LAKOMY, R. VYZULA, I. KISS, Ladislav DUŠEK a T. BUEHLER. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. New York: ELSEVIER SCIENCE INC., 2014, roč. 32, č. 4, s. 488-495. ISSN 1078-1439. Dostupné z: https://dx.doi.org/10.1016/j.urolonc.2013.09.011. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1185400,
author = {Poprach, A. and Pavlík, Tomáš and Melichar, B. and Kubackova, K. and Bortlíček, Zbyněk and Svoboda, M. and Lakomy, R. and Vyzula, R. and Kiss, I. and Dušek, Ladislav and Buehler, T.},
article_location = {New York},
article_number = {4},
doi = {http://dx.doi.org/10.1016/j.urolonc.2013.09.011},
keywords = {renal cell carcinoma; prognosis; survival; sunitinib; sorafenib},
language = {eng},
issn = {1078-1439},
journal = {UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS},
title = {Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines},
volume = {32},
year = {2014}
}
TY - JOUR
ID - 1185400
AU - Poprach, A. - Pavlík, Tomáš - Melichar, B. - Kubackova, K. - Bortlíček, Zbyněk - Svoboda, M. - Lakomy, R. - Vyzula, R. - Kiss, I. - Dušek, Ladislav - Buehler, T.
PY - 2014
TI - Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines
JF - UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
VL - 32
IS - 4
SP - 488-495
EP - 488-495
PB - ELSEVIER SCIENCE INC.
SN - 10781439
KW - renal cell carcinoma
KW - prognosis
KW - survival
KW - sunitinib
KW - sorafenib
N2 - Objectives: The aim of this retrospective study was to analyze prognostic factors in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors (TKIs) sunitinib or sorafenib after progression on cytokine therapy. Materials and methods: A national database of patients treated with targeted agents was used as the data source. A total of 319 patients treated with sunitinib (n = 181) or sorafenib (n = 138) after progression on cytokine therapy were analyzed. Results: Prognostic factors significantly associated with poor overall survival in a multivariable Cox model included the time from diagnosis to the start of treatment with TKIs <1 year, increased neutrophil counts, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. The parameters showing statistically significant association with progression-free survival included time from diagnosis to the beginning of treatment with TKI <1 year, increased lactate dehydrogenase, and Eastern Oncology Cooperative Group performance status 2 or higher. We have also validated the International Metastatic Renal Cell Carcinoma Database Consortium prognostic model in our cohort of patients. Conclusion: We demonstrate that the International Database Consortium prognostic model performs well for European patients treated with TKIs, including sunitinib or sorafenib, after progression on cytokines and suggest that a reduction from original 6 down to 4 parameters is possible.
ER -
POPRACH, A., Tomáš PAVLÍK, B. MELICHAR, K. KUBACKOVA, Zbyněk BORTLÍČEK, M. SVOBODA, R. LAKOMY, R. VYZULA, I. KISS, Ladislav DUŠEK a T. BUEHLER. Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines. \textit{UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS}. New York: ELSEVIER SCIENCE INC., 2014, roč.~32, č.~4, s.~488-495. ISSN~1078-1439. Dostupné z: https://dx.doi.org/10.1016/j.urolonc.2013.09.011.
|
